Floatz logo

Zanzalintinib

Renal Cell Carcinoma

City of Hope Medical CenterSmall moleculePhase 3Active
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
65/ 100
Competitive Position
65/ 100

Competitive context

270 Active assets in the Renal Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Sorafenib
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 4BBB
Pazopanib
Imbioray (Hangzhou) Biomedicine Co., Ltd.
Phase 4BBB
Belzutifan
Vall d'Hebron Institute of Oncology
Phase 3BBB
Cyclosporin A
National Cancer Institute (NCI)
Phase 2BB
Interferon-Alfa-2A
Central European Society for Anticancer Drug Research
Phase 3BB

View all 50 →

Same molecule, other indications

Zanzalintinib is also rated in:

pancreatic neuroendocrine tumorActive
BB
Indicative · Phase 3
66 / 100
View asset →
hepatocellular carcinomaActive
BB
Indicative · Phase 3
65 / 100
View asset →
nonpapillary renal cell carcinomaActive
B
Indicative · Phase 2
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →